8 completed. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 3 | Completed 3 |
Follow ENMD 2076: new trials by email Literature Review of ENMD 2076 trials Research Report on ENMD 2076
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma ENMD-2076 - Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma | Phase 2 | Completed | CASI pharmaceuticals, Inc. | 35 | 2015-10-01 | 2025-04-18 |
| A Study of ENMD-2076 in Ovarian Clear Cell Cancers ENMD-2076 - Ovarian Clear Cell Carcinoma | Phase 2 | Completed | University Health Network, Toronto | 40 | 2013-09-01 | 2019-12-13 |
| Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma ENMD-2076 - Advanced, Metastatic | Phase 2 | Completed | University Health Network, Toronto | 25 | 2013-01-01 | 2023-08-01 |
| Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC ENMD-2076 - Triple Negative Breast Cancer | Phase 2 | Completed | CASI pharmaceuticals, Inc. | 41 | 2012-07-01 | 2017-06-26 |
| Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer ENMD-2076 - Ovarian Cancer, Fallopian Cancer | Phase 2 | Completed | CASI pharmaceuticals, Inc. | 64 | 2010-04-01 | 2014-08-06 |
| Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies ENMD-2076 - Relapsed or Refractory Hematological Malignancies | Phase 1 | Completed | CASI pharmaceuticals, Inc. | 27 | 2009-04-01 | 2011-08-04 |
| Study of ENMD-2076 in Patients With Multiple Myeloma ENMD-2076 - Multiple Myeloma | Phase 1 | Completed | CASI pharmaceuticals, Inc. | 13 | 2008-12-01 | 2023-02-06 |
| A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer ENMD-2076 - Advanced Cancer | Phase 1 | Completed | CASI pharmaceuticals, Inc. | 67 | 2008-04-01 | 2023-02-06 |
Breast Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Recurrence (1) · Sarcoma (1) · Triple Negative Breast Neoplasms (1)
CASI pharmaceuticals, Inc. (6) · University Health Network, Toronto (2)
United States (5) · Canada (4) · China (1)
William Gannon, MD, MBA (2) · Albiruni Razak, MBBS (1) · Amit Oza, M.D. (1) · Ghassan Abou-Alfa, MD (1) · Ken Ren, PhD (1) · Rong Chen, MD (1)